VYNE Therapeutics Future Growth

Future criteria checks 2/6

VYNE Therapeutics's earnings are forecast to decline at 13.1% per annum while its annual revenue is expected to grow at 79.2% per year. EPS is expected to grow by 15.8% per annum.

Key information

-13.1%

Earnings growth rate

15.8%

EPS growth rate

Pharmaceuticals earnings growth	22.9%
Revenue growth rate	79.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	29 Feb 2024

Recent future growth updates

Recent updates

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

May 04

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10

VYNE Therapeutics closes capital raise of $50M

Jan 29

What Is The Ownership Structure Like For VYNE Therapeutics Inc. (NASDAQ:VYNE)?

Jan 06

VYNE Therapeutics reports successful FDA meeting for FCD105 in acne

Dec 17

Have Insiders Been Buying VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares?

Dec 08

Earnings and Revenue Growth Forecasts

NasdaqCM:VYNE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	0	-46	N/A	N/A	2
12/31/2025	0	-41	N/A	N/A	2
12/31/2024	0	-33	N/A	N/A	1
12/31/2023	0	-28	-25	-25	N/A
9/30/2023	0	-29	-25	-25	N/A
6/30/2023	0	-33	-27	-27	N/A
3/31/2023	0	-31	-26	-26	N/A
12/31/2022	0	-34	-29	-29	N/A
9/30/2022	1	-35	-34	-34	N/A
6/30/2022	1	-40	-45	-45	N/A
3/31/2022	1	-42	-53	-53	N/A
12/31/2021	1	-44	-56	-56	N/A
9/30/2021	5	-59	-72	-72	N/A
6/30/2021	8	-69	-78	-78	N/A
3/31/2021	19	-226	-97	-97	N/A
12/31/2020	21	-256	-137	-137	N/A
9/30/2020	17	-270	-134	-134	N/A
6/30/2020	14	-269	-133	-132	N/A
3/31/2020	2	-120	-110	-109	N/A
12/31/2019	0	-95	-74	-73	N/A
9/30/2019	1	-71	-63	-62	N/A
6/30/2019	2	-64	-62	-62	N/A
3/31/2019	3	-63	-63	-62	N/A
12/31/2018	4	-74	-69	-69	N/A
9/30/2018	4	-77	-71	-70	N/A
6/30/2018	4	-80	-70	-69	N/A
3/31/2018	4	-77	-66	-64	N/A
12/31/2017	4	-66	-55	-53	N/A
9/30/2017	4	-59	N/A	-53	N/A
6/30/2017	6	-47	N/A	-36	N/A
3/31/2017	6	-39	N/A	-32	N/A
12/31/2016	6	-29	N/A	-27	N/A
9/30/2016	4	-24	N/A	-18	N/A
6/30/2016	2	-21	N/A	-19	N/A
3/31/2016	1	-18	N/A	-18	N/A
12/31/2015	1	-17	N/A	-12	N/A
9/30/2015	4	-11	N/A	-10	N/A
6/30/2015	4	-16	N/A	-7	N/A
3/31/2015	4	-15	N/A	-4	N/A
12/31/2014	5	-11	N/A	-1	N/A
9/30/2014	3	-12	N/A	1	N/A
6/30/2014	3	-4	N/A	1	N/A
3/31/2014	3	-2	N/A	2	N/A
12/31/2013	1	-2	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VYNE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VYNE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VYNE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VYNE's revenue (79.2% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: VYNE's revenue (79.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VYNE's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

VYNE Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Price target increased by 21% to US$16.50

Consensus revenue estimates increase by 60%, EPS downgraded

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

Consensus forecasts updated

Recent updates

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics Inc. Announces Results from Its Phase 2a Trial of FMX114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$5.80

High number of new and inexperienced directors

VYNE Therapeutics Inc. Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an in Vivo Model of Rheumatoid Arthritis

Consensus forecasts updated

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Lead Bet Inhibitor, VYN201, in Human Skin Model of Vitiligo

VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for the Treatment of Mild-To-Moderate Atopic Dermatitis

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Price target increased to US$5.80

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.59 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$4.83 loss in 2Q 2020)

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

VYNE Therapeutics Inc. Announces Approval of Amzeeq (Minocycline) and Zilxi (Minocycline) in Chinese Economic Pilot Zone

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne

Vyne Therapeutics Receives A Paragraph IV Certification Notice from Perrigo Israel Pharmaceuticals Advising That Perrigo Has Submitted to the FDA

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

VYNE Therapeutics Inc.(NasdaqGS:VYNE) dropped from Russell 2000 Dynamic Index

Forecast breakeven pushed back to 2024

CFO & Treasurer Andrew Saik has left the company

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Price target decreased to US$12.71

First quarter 2021 earnings released: US$0.42 loss per share (vs US$3.79 loss in 1Q 2020)

Director recently bought US$93k worth of stock

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$7.88 loss per share (vs US$6.65 loss in FY 2019)

Analysts update estimates

VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-To-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. to Report Fiscal Year 2020 Results on Mar 04, 2021

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts